Back to Search Start Over

Supplementary Tables from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia

Supplementary Tables from Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia

Authors :
Eric Padron
Rami S. Komrokji
Mikkael A. Sekeres
Alan F. List
Jeffrey E. Lancet
Hailing Zhang
Traci Kruer
Markus Ball
Maria E. Balasis
Christopher Letson
William Dominguez-Viqueira
David A. Sallman
Aaron Gerds
Onyee Chan
Qianxing Mo
Gail J. Roboz
Sandrine Niyongere
David P. Steensma
Amy E. Dezern
Hannah Newman
Anthony M. Hunter
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Supplementary Table S1 details the IWG response criteria for MDS/MPNs. Supplementary Table S2 summarizes grade 3 and 4 treatment-emergent toxicities. Supplementary Table S3 summarizes all recorded adverse events. Supplementary Table S4 summarizes the reasons for treatment discontinuation. Supplementary Table S5 details the baseline characteristics of patients from which patient-derived xenograft mice were generated.

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....546a01d27e36ac313485050cabac7a27
Full Text :
https://doi.org/10.1158/1078-0432.22480698.v1